메뉴 건너뛰기
소속 기관 / 학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
고객센터 ENG
주제분류

논문 기본 정보

저자정보
출처
Springer Science and Business Media LLC Scientific Reports 16(1)
오류 신고하기
표지

검색

    초록·키워드

    Ipratropium bromide (IB), identified through an artificial intelligence (AI)-aided drug screening platform, was evaluated for its safety and efficacy in treating severe coronavirus disease 2019 (COVID-19) using a hamster model in this study. The mortality rates in the vehicle, remdesivir-treated, IB-treated, and IB-remdesivir combination treatment groups were 70%, 15%, 5%, and 50%, respectively. The IB-treated group showed significantly lower blood D-dimer levels and fibrin degradation product when compared to that in the vehicle group, indicating prevention of thrombosis-related complications. Histological examination also revealed reduced lung inflammation in the IB and combination groups, compared to that in the vehicle and remdesivir groups, with fewer neutrophils in bronchoalveolar lavage fluid. Moreover, IB may prevent thrombosis-related complications caused by severe COVID-19.

    본문·목차

    최근 본 자료 전체보기